Chaoju Eye Care Holdings Ltd. (HK:2219)
:2219
Top Page
Chaoju Eye Care Holdings Ltd.
(2219)
Select Model
Select Model
Rating:68Neutral
Price Target:
HK$3.00
â–²(10.70% Upside)
Action:DowngradedDate:09/02/25
Chaoju Eye Care Holdings Ltd. has a solid financial foundation and attractive valuation, which are significant strengths. However, the technical analysis indicates bearish momentum, which is a concern. The absence of earnings call insights and corporate events means these factors do not influence the score.
Positive Factors
Revenue Growth
Consistent revenue growth indicates strong demand for services and effective market positioning, supporting long-term business expansion.
Negative Factors
Net Profit Margin Decline
A declining net profit margin may signal cost pressures or inefficiencies, potentially impacting profitability and requiring strategic cost management.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Consistent revenue growth indicates strong demand for services and effective market positioning, supporting long-term business expansion.
Read all positive factors
Chaoju Eye Care Holdings Ltd. (2219) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$1.94B
Dividend Yield9.29%
Average Volume (3M)722.53K
Price to Earnings (P/E)4.1
Beta (1Y)0.76
Revenue Growth-3.19%
EPS Growth-20.30%
CountryHK
Employees2,608
SectorHealthcare
Sector Strength45
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)0.11
Shares Outstanding705,180,500
10 Day Avg. Volume521,468
30 Day Avg. Volume722,533
Financial Highlights & Ratios
PEG Ratio-0.63
Price to Book (P/B)0.81
Price to Sales (P/S)1.33
P/FCF Ratio5.26
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.25
Revenue Forecast (FY)HK$1.47B
Chaoju Eye Care Holdings Ltd. Business Overview & Revenue Model
Company Description
Chaoju Eye Care Holdings Limited owns and operates a network of ophthalmic hospitals and optical centers in China. Its consumer ophthalmic services include treatments and prevention for various ophthalmic disorders, such as refractive and presbyop...
How the Company Makes Money
Chaoju Eye Care Holdings Ltd. generates revenue through multiple streams, primarily from the sale of its core products such as intraocular lenses and surgical instruments used in eye care procedures. The company benefits from a growing demand for ...
Chaoju Eye Care Holdings Ltd. Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
75
Positive
Cash Flow
81
Very Positive
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.37B | 1.41B | 1.37B | 990.04M | 997.79M | 794.28M |
| Gross Profit | 573.00M | 611.30M | 621.13M | 434.70M | 448.67M | 349.48M |
| EBITDA | 316.81M | 335.37M | 434.82M | 267.87M | 304.65M | 225.18M |
| Net Income | 172.27M | 195.08M | 228.91M | 187.75M | 161.75M | 124.14M |
Balance Sheet | ||||||
| Total Assets | 3.00B | 2.88B | 2.92B | 2.72B | 2.51B | 1.09B |
| Cash, Cash Equivalents and Short-Term Investments | 1.47B | 1.54B | 1.55B | 1.68B | 1.78B | 413.25M |
| Total Debt | 253.76M | 218.01M | 200.80M | 196.16M | 178.65M | 142.36M |
| Total Liabilities | 638.53M | 554.76M | 544.38M | 424.68M | 378.11M | 325.48M |
| Stockholders Equity | 2.35B | 2.32B | 2.36B | 2.27B | 2.11B | 737.25M |
Cash Flow | ||||||
| Free Cash Flow | 279.75M | 354.36M | 286.02M | 148.29M | 189.18M | 196.16M |
| Operating Cash Flow | 361.45M | 354.36M | 372.57M | 273.41M | 249.39M | 248.75M |
| Investing Cash Flow | -315.07M | 245.36M | -654.10M | -464.77M | -578.51M | -35.45M |
| Financing Cash Flow | -160.85M | -292.30M | -204.01M | -165.43M | 1.19B | -39.61M |
Chaoju Eye Care Holdings Ltd. Technical Analysis
Positive
2.71
Price Trends
2.66
Positive
2.64
Positive
2.73
Positive
Market Momentum
>-0.01
Negative
63.91
Neutral
76.03
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2219, the sentiment is Positive. The current price of 2.71 is above the 20-day moving average (MA) of 2.57, above the 50-day MA of 2.66, and below the 200-day MA of 2.73, indicating a bullish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 63.91 is Neutral, neither overbought nor oversold. The STOCH value of 76.03 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:2219.
Chaoju Eye Care Holdings Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | HK$678.82M | 3.30 | 5.29% | 9.14% | 0.47% | 50.46% | |
69 Neutral | HK$863.39M | 5.69 | 6.49% | 1.99% | -1.61% | -27.39% | |
68 Neutral | HK$1.94B | 4.06 | 7.38% | 9.29% | -3.19% | -20.30% | |
66 Neutral | HK$1.32B | 1.62 | 18.05% | 4.37% | -3.56% | -17.45% | |
52 Neutral | HK$1.69B | 117.78 | 0.48% | 0.49% | -0.55% | 45.36% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | HK$1.61B | 20.66 | 5.64% | 1.20% | 2.05% | -285.88% |
* Healthcare Sector Average
HK:2219
Chaoju Eye Care Holdings Ltd.
2.75
0.37
15.55%
HK:1526
Rici Healthcare Holdings Ltd.
0.83
-0.27
-24.55%
HK:1846
EuroEyes International Eye Clinic Limited
2.70
-0.19
-6.57%
HK:3309
C-MER Eye Care Holdings Limited
1.31
-0.09
-6.43%
HK:3689
Guangdong Kanghua Healthcare Co., Ltd. Class H
2.03
0.21
11.54%
HK:3886
Town Health International Medical Group Ltd.
0.25
0.02
8.23%
Chaoju Eye Care Holdings Ltd. Corporate Events
Chaoju Eye Care Wins Three-Year Waiver to Appoint Executive Director as Joint Company Secretary
Jan 7, 2026
Chaoju Eye Care Holdings has appointed executive director Zhang Guangdi as joint company secretary for a three-year term effective 7 January 2026, alongside existing joint company secretary Lo Wai Kin Kent. Zhang, who has extensive management expe...
Chaoju Eye Care Revamps Company Secretary Roles and Seeks New Listing Rules Waiver
Jan 2, 2026
Chaoju Eye Care Holdings has announced a reshuffle of its corporate governance and compliance functions, with joint company secretary and authorised representative Mr. Cheng Ching Kit resigning from his roles, including as process agent, effective...
Chaoju Eye Care Announces HK$50 Million Share Repurchase Plan
Nov 18, 2025
Chaoju Eye Care Holdings Ltd. has announced its intention to conduct an on-market share repurchase of up to HK$50 million, demonstrating confidence in its business outlook and aiming to create value for its shareholders. This move, subject to mark...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.